Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

ABSTRACT: We report long-term clinical and immunologic outcomes from the MM1636 trial (NCT03047928), which evaluated a peptide vaccine targeting IDO and PD-L1 in combination with nivolumab in patients with advanced melanoma. At a five-year follow-up, the combination demonstrated durable clinical efficacy, with a 25.5-month median progression-free survival. Serum proteomic profiling identified vaccine-specific immune signatures, with increase in CCL3, CCL4, and TNFα emerging as biomarkers of long progression-free survival. Increase in these markers were not observed in a matched anti-PD-1 monotherapy cohort, suggesting distinct immune modulation by the vaccine. Functional studies confirmed vaccine-induced targeting of myeloid cells and associated increase in these cytokines. These findings provide ev

SUBMITTER: Pedersen S 

PROVIDER: S-EPMC12824258 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature